Humacyte secures $1.5M Saudi order – why did HUMA stock crash to record low today?
Humacyte (HUMA) announced a $1.5 million order from Saudi Arabia for its Vasculogen artificial vessels, intended for treating vascular trauma. Despite this positive news, the company's stock experienced a significant drop, hitting a new all-time low. This decline is likely attributed to a previously announced public offering and concurrent private placement of its securities, which could dilute existing shareholder value.
Humacyte (HUMA) director Kathleen Sebelius purchases 56,818 shares at $0.88
Humacyte, Inc. director Kathleen Sebelius purchased 56,818 shares of the company's common stock at $0.88 per share on May 19, 2026, in an open-market transaction. This transaction increased her direct holdings to a total of 148,025 shares. The filing, a Form 4, indicates a net buy of $50,000 worth of shares, signaling insider confidence.
High-Profile Director Makes Bold Move Into Humacyte Shares
Humacyte (HUMA) Director Kathleen Sebelius recently purchased 56,818 shares of the company's stock for $49,999, signaling insider confidence. This move follows news of Humacyte's Symvess graft securing a contract with the U.S. Department of Veterans Affairs, which is expected to boost sales. Despite strong early commercial traction and growth prospects, TipRanks' AI Analyst Spark views HUMA as Neutral due to weak financial performance, though technical momentum is improving, with key clinical trial results anticipated by June 11, 2026.
Humacyte (HUMA) director adds 11,000 shares at about $0.89
Humacyte, Inc. director Michael T. Constantino purchased 11,000 shares of the company's common stock on May 18, 2026, at a weighted average price of $0.8945 per share in open-market transactions. This purchase increased his direct holdings to 43,950 common shares. The acquisition was reported in a Form 4 filing, with shares bought within a price range of $0.8922 to $0.8958.
Humacyte (HUMA) CMO executes 45,887-share tax sell-to-cover under 10b5-1 plan
Humacyte, Inc.'s Chief Medical Officer, Shamik J. Parikh, engaged in an automated "sell-to-cover" transaction, disposing of 45,887 shares of common stock at an average price of $0.8967 per share. This sale was non-discretionary and executed under a Rule 10b5-1(c) trading plan to satisfy statutory tax withholding obligations tied to the vesting of restricted stock units. Following this transaction, Parikh directly holds 272,713 shares of Humacyte common stock.
Humacyte (HUMA) CFO executes 45,887-share sell-to-cover trade for RSU taxes
Humacyte, Inc. CFO Dale A. Sander sold 45,887 shares of common stock at an average price of $0.8967 per share. This transaction was an automated "sell-to-cover" sale to pay statutory tax withholding obligations from vested restricted stock units, conducted under a pre-arranged Rule 10b5-1 plan. Post-sale, Sander directly holds 267,213 shares and indirectly holds 40,600 shares through his spouse.
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs
Humacyte announced that its product, Symvess, is now under contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs. This contract will make Symvess more accessible to 170 VA hospitals as SAC awards streamline the approval process through intensive product and value analysis. Symvess was approved by the FDA in December 2024 for extremity vascular trauma.
Humacyte’s Symvess added to VA hospital contract system
Humacyte's product Symvess has been added to the Strategic Acquisition Center (SAC) contract of the U.S. Department of Veterans Affairs, making it accessible to 170 VA hospitals. Despite a recent stock decline, the company boasts significant revenue growth and analyst predictions of continued sales. Symvess received FDA approval in December 2024 for extremity vascular trauma, with other bioengineered tissue applications in late-stage clinical trials.
VA hospitals to get easier access to Humacyte Symvess product
Humacyte's bioengineered vessel product, Symvess, has been added to the U.S. Department of Veterans Affairs’ Strategic Acquisition Center (SAC) contract through the Surgical Implant – Next Generation (SING) program. This agreement makes Symvess more accessible to approximately 170 VA hospitals, having undergone intensive product and value analysis vetting by a surgical committee. Symvess received FDA approval in December 2024 for extremity vascular trauma, while remaining investigational for other uses.
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
Humacyte, Inc. (HUMA) recently had its price target raised by TD Cowen to $1.50 from $1.00, reiterating a Buy rating. This positive outlook follows the company's Q1 2026 results, showing increased Symvess sales and significant long-term growth potential in vascular trauma and broader indications like arteriovenous access and peripheral artery disease. Despite a widening net loss and increased R&D expenses, the bioengineered tissue developer remains a focus for its flagship product, Symvess.
[144] Humacyte, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Humacyte, Inc. (HUMA) dated May 18, 2026, indicating a proposed sale of securities. The filing details the securities to be sold, their acquisition, and filer information, with a neutral impact and sentiment attributed to the filing. It also includes recent news and SEC filings for Humacyte, Inc.
Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global Agreements
Humacyte (HUMA) is under evaluation after its Q1 2026 results revealed continued losses, alongside new leadership, cost cuts, fresh capital, and international agreements. The company's stock has been volatile, with a significant 1-year decline, despite recent gains, as investors weigh compliance risks and upcoming clinical milestones. Simply Wall St's analysis suggests Humacyte may be 95.9% undervalued with a Fair Value of $22.83 against its current trading price of $0.93, contingent on Symvess adoption and dialysis trial progress.
Number of shareholders of Humacyte, Inc. – NASDAQ:HUMA
This page from TradingView provides financial information for Humacyte, Inc. (NASDAQ: HUMA), including its number of shareholders. It is part of a larger platform offering market data, charting tools, and community features for investors.
Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM), Humacyte (HUMA) and Revvity (RVTY)
Healthcare analysts have issued conflicting ratings for several companies. David Dai from UBS maintained a Buy rating for Cullinan Management (CGEM), while Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating for Humacyte (HUMA). In contrast, Michael Ryskin from Bank of America Securities maintained a Hold rating on Revvity (RVTY).
Triangle biotech cuts 25% of workforce in commercial reset
Humacyte, a Triangle-based biotech company, is reducing its workforce by 25% as part of a significant commercial strategy revamp. This move follows a period of slow sales and challenges, aiming to reset their approach to the market. The company is located at 2525 E. N.C. Highway 54 Durham.
Does Humacyte’s (HUMA) Nasdaq Notice Quietly Reframe Its Financing Flexibility And Clinical Adoption Story?
Humacyte (HUMA) reported a significant net loss in Q1 2026 and received a Nasdaq notice due to its share price falling below the minimum US$1.00 requirement, raising concerns about its financial stability and listing status. Despite appointing a new Chief Surgical Officer to boost clinical adoption of Symvess, the company faces immediate risks related to financing and achieving commercial traction for its bioengineered vessels. Analysts' forecasts for revenue and profitability vary, with some suggesting a cautious outlook compared to the company's more optimistic projections.
Humacyte, Inc. (NASDAQ:HUMA) Q1 2026 Earnings Call Transcript
Humacyte, Inc. (NASDAQ:HUMA) reported Q1 2026 earnings, beating expectations with an EPS of $-0.09. The company announced first-quarter sales of Symvess at $0.5 million, up from $0.1 million in Q1 2025, and provided updates on its commercialization efforts, including new leadership hires and international expansion. Humacyte also discussed the upcoming interim results of its V012 Phase III trial for dialysis access, plans for a supplemental BLA submission, and a workforce restructuring resulting in a $14.3 million estimated savings for the remainder of 2026.
Humacyte Cuts 25% of Workforce
Humacyte, a biotechnology company, has announced a 25% reduction in its workforce, eliminating approximately 45 employees and saving an estimated $14.3 million for the remainder of 2026. This decision follows Q1 2026 earnings that showed a revenue miss despite increased commercial sales for its Symvess vascular trauma implant. The company is intensifying commercial efforts, securing international commitments, and preparing to release crucial Phase 3 trial data in June.
HUMA: Symvess sales surged, restructuring cut costs, and key clinical milestones are on track for 2026
Humacyte (HUMA) reported a fivefold year-over-year increase in Symvess sales for the first quarter of 2026, attributed to expanded market efforts and a new commercial strategy. The company anticipates interim phase III dialysis trial results in June and plans a supplemental BLA filing for late 2026. This positive outlook is supported by recent restructuring efforts that have reduced costs.
Humacyte Releases Q1 2026 Financial Results
Humacyte, Inc. (HUMA) announced its Q1 2026 financial results, reporting a diluted net loss per share of $0.09, which was narrower than the estimated -$0.12. The company generated $495,000 in revenue, a slight decrease from the previous year, and recorded a net loss of $17.6 million for the quarter. Symvess product revenue contributed $493,000 to the total.
Humacyte cuts spending, staff as it seeks to boost sluggish sales for its off-the-shelf artery implant
Humacyte is undergoing significant cost-cutting measures, including a 25% workforce reduction affecting about 45 employees and $14.3 million in spending cuts, to address sluggish sales of its Symvess artery implant. Despite the FDA approval in December 2024, the device generated only $500,000 in Q1 2026 sales against $2 million in cost of goods sold. The company, which is also maintaining a focus on sales and marketing, is developing its engineered vessel platform for other uses, including a phase 3 trial in hemodialysis with results expected next month.
Bioengineered blood vessel firm wins Saudi deal and Pentagon backing
Humacyte (Nasdaq: HUMA) reported Q1 2026 financial results, including $0.5 million in Symvess sales and a net loss of $17.6 million. The company announced significant business developments, such as a $1.475 million Symvess purchase commitment in Saudi Arabia, acceptance of a marketing authorization application in Israel, and new U.S. Department of Defense funding for bioengineered blood vessels. Additionally, Humacyte detailed a workforce restructuring anticipated to save $14.3 million through 2026 and confirmed interim Phase 3 hemodialysis results are expected in June 2026.
Humacyte Names Vascular Surgery Pioneer Todd Rasmussen Chief Surgical Officer
Humacyte has appointed Dr. Todd E. Rasmussen, a renowned vascular surgeon and pioneer in the field, as its Chief Surgical Officer. This strategic hire aims to bolster Humacyte's commercialization efforts for its FDA-approved bioengineered vascular tissue, Symvess, and advance other late-stage product candidates. Dr. Rasmussen will focus on surgeon education, scientific engagement, and technical support to drive the adoption of Humacyte's regenerative medicine technologies in clinical settings.
Todd Rasmussen joins Humacyte as chief surgical officer
Todd E. Rasmussen, a distinguished vascular surgeon from Mayo Clinic, has been appointed as Humacyte's chief surgical officer. In this role, Rasmussen will provide scientific support, medical education, and technical insights to healthcare providers, leveraging his extensive experience in vascular surgery and military service to optimize the integration of Humacyte's products into clinical practice. His appointment is expected to be invaluable as Humacyte forges ahead with its Symvess product, aiming to expand durable vascular access options for patients.
Humacyte appoints Todd Rasmussen as chief surgical officer
Humacyte, Inc. (NASDAQ:HUMA) has appointed Todd E. Rasmussen, M.D., as its Chief Surgical Officer. Dr. Rasmussen, a veteran of the U.S. Air Force and current professor at Mayo Clinic, will provide scientific support and clinical insights for Humacyte's products, including their FDA-approved acellular tissue engineered vessel. This comes as Humacyte anticipates significant revenue growth in 2026 and continues late-stage clinical trials for other vascular applications.
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer
Humacyte, Inc. (Nasdaq: HUMA) has appointed Dr. Todd E. Rasmussen as its Chief Surgical Officer. Dr. Rasmussen, a distinguished vascular surgeon with decades of clinical experience and leadership, will provide scientific support, medical education, and technical insights to surgeons, particularly as the clinical adoption of Humacyte’s product Symvess® expands and pipeline indications move towards approval. He will continue his responsibilities at Mayo Clinic concurrently with this new role.
Military surgeon joins Humacyte to guide off-the-shelf biologic conduit
Humacyte (Nasdaq: HUMA) has appointed Dr. Todd E. Rasmussen as its Chief Surgical Officer. Dr. Rasmussen, a distinguished vascular surgeon with 28 years of U.S. Air Force experience and deep expertise in vascular surgery and trauma care, will provide scientific support and technical insights for the optimal implantation of Humacyte’s bioengineered vascular products, including Symvess. This strategic hire aims to strengthen the company’s clinical and commercial infrastructure as it advances its product pipeline and commercial adoption.
Humacyte Inc expected to post a loss of 12 cents a share - Earnings Preview
Humacyte Inc is projected to report an earnings loss of 12 cents per share. This information comes from an earnings preview provided by Refinitiv. The article is a brief news update regarding the company's financial outlook.
Humacyte Receives Nasdaq Notice on Minimum Bid Requirement
Humacyte (HUMA) has received a notice from Nasdaq due to its shares closing below the $1.00 minimum bid requirement for 30 consecutive business days, putting its Nasdaq Global Select Market listing at risk. The company has until November 2, 2026, to regain compliance. While analysts currently rate HUMA as a "Buy" with a $3.00 price target, TipRanks' AI Analyst, Spark, assesses it as "Neutral" due to weak financial performance and high leverage.
Humacyte Receives Nasdaq Notice on Minimum Bid Requirement
Humacyte (HUMA) received a Nasdaq notice because its shares traded below the $1.00 minimum bid requirement for 30 consecutive days. The company has until November 2, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Nasdaq analysts rate HUMA as a Buy, with a price target of $3.00, while TipRanks' AI Analyst Spark rates it as Neutral due to weak financial performance despite a positive short-term technical trend.
Humacyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Humacyte (HUMA) received a notice from Nasdaq on May 4, 2026, stating that its common stock failed to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has until November 2, 2026, to regain compliance by achieving a $1.00 or higher closing bid for at least 10 consecutive business days. Humacyte shares will continue to trade on the Nasdaq Global Select Market under the ticker HUMA.
Humacyte Receives Nasdaq Notice on Minimum Bid Requirement
Humacyte (HUMA) has received a notice from Nasdaq stating its shares traded below the $1.00 minimum bid requirement for 30 consecutive business days, risking its Nasdaq Global Select Market listing. The company has until November 2, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. An analyst has a Buy rating with a $3.00 price target, but TipRanks' AI Analyst, Spark, rates HUMA as Neutral due to weak financial performance and high leverage.
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Humacyte, Inc. (HUMA) following a securities class action lawsuit. This lawsuit alleges that Humacyte failed to disclose material information after the FDA extended its review of the company's Biologic License Application and subsequently issued a Form 483 citing manufacturing violations. KSF's investigation focuses on potential breaches of fiduciary duty by Humacyte's officers and directors.
Humacyte (NASDAQ: HUMA) faces 180-day window to fix Nasdaq $1 bid-price deficiency
Humacyte (NASDAQ: HUMA) has received a notice from Nasdaq due to its common stock trading below the required $1.00 per share for 30 consecutive business days. The company now has 180 calendar days, until November 2, 2026, to regain compliance by having its closing bid price at or above $1.00 for at least 10 consecutive business days. Failure to meet this requirement could lead to delisting, although trading and reporting obligations currently remain unaffected.
Earnings Preview: Humacyte to Report Financial Results Pre-market on May 13
Humacyte (NASDAQ: HUMA) is scheduled to release its financial results for the first quarter of 2026 before the market opens on Monday, May 13. The company will also host a conference call and webcast to discuss these results later that day. Analysts anticipate a loss of $0.23 per share and revenue of $0.25 million for the quarter.
Biotech firm Humacyte will give investors a business update May 13
Humacyte (Nasdaq: HUMA) will release its Q1 2026 financial results and provide a business update on May 13, 2026, at 8:00 a.m. ET via a webcast and conference call. The company, a commercial-stage developer of bioengineered human tissues, received FDA approval in December 2024 for its Symvess ATEV for vascular trauma and is conducting late-stage trials for other applications. This announcement precedes a day of elevated trading volume for HUMA stock.
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why
Humacyte, Inc. (HUMA) stock fell by 1.16% on May 5, 2026, closing at $1.70, despite a positive day for the broader stock market. The decline reflects the stock's recent underperformance, including a 16.67% drop over the last month and a 17.16% year-to-date loss. Investors will be watching for the company's upcoming earnings report on May 13, 2026.
Humacyte (HUMA) Motion to Dismiss Ruling Keeps Key Securities Claims Alive
A federal judge has partially denied Humacyte's motion to dismiss an investor lawsuit, allowing claims regarding misleading statements about the safety and efficacy of its product, Symvess, to proceed. However, claims related to manufacturing readiness and liquidity disclosures were dismissed without prejudice. The case will now focus on Humacyte's statements regarding Symvess's safety profile and clinical performance during the class period.
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of "Moderate Buy" from Brokerages
Eight analysts have given Humacyte, Inc. (NASDAQ:HUMA) a consensus "Moderate Buy" rating, with an average price target of $7.7143, significantly higher than its current share price of around $0.86. Despite this optimistic average, analyst opinions vary widely, reflecting significant disagreement on the company's prospects. Humacyte, a clinical-stage biotech, reported mixed financial results in its last quarter and has negative profitability metrics, alongside approximately 44.7% institutional ownership.
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing
Humacyte, Inc. (HUMA) has demonstrated strong stock performance, outperforming the S&P 500 year-to-date and over the past month. The article highlights key financial metrics that investors should consider, such as sales growth expectations, earnings per share, and price-to-sales ratio, to understand the company's current valuation and future prospects. These metrics can help in evaluating the stock's potential for continued outperformance.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
Faruqi & Faruqi, LLP is investigating potential claims against Humacyte, Inc. (NASDAQ: HUMA) on behalf of investors who suffered losses exceeding $75,000 between May 10, 2024, and October 17, 2024. The firm reminds investors of the January 17, 2025, deadline to seek the role of lead plaintiff in a federal securities class action, alleging Humacyte made misleading statements regarding its manufacturing practices and the FDA approval process for its ATEV product. The stock declined significantly after disclosures about FDA facility violations and delayed BLA review.
Humacyte stock price target reiterated at $3 by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating and a $3.00 price target for Humacyte (NASDAQ:HUMA) after a key opinion leader call discussing the market opportunity for its Symvess product. The company's stock has seen a significant surge recently, trading at $0.85 with a market cap of $188 million, and is focused on the V012 Phase 3 study for its acellular tissue engineered vessel for women with end-stage kidney disease on hemodialysis. Interim results for this study are expected in June 2026, though the company is currently burning through cash and has seen reduced price targets from other analysts due to lower-than-expected revenue and sales.
D. Boral Capital Reaffirms "Buy" Rating for Humacyte (NASDAQ:HUMA)
D. Boral Capital has reaffirmed a "Buy" rating for Humacyte (NASDAQ:HUMA) with a price target of $25.00, according to a Benzinga report. Despite this, analyst views are mixed, with a "Moderate Buy" consensus and an average target of $7.71 from several firms that have issued sell or strong-sell ratings. Humacyte, a clinical-stage biotech focused on off-the-shelf HAVs, is trading around $0.84, reported a revenue miss, and analysts forecast continued losses.
BTIG Research Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)
BTIG Research has reaffirmed a "buy" rating for Humacyte (NASDAQ:HUMA), setting a $3.00 price target that suggests a 287.6% upside. Despite the positive analyst outlook and significant institutional ownership, Humacyte reported a quarterly EPS miss and negative margins, with shares currently trading around $0.77. The company specializes in developing regenerative human acellular vessels for vascular access needs.
Humacyte (NASDAQ: HUMA) 2026 proxy adds share increase vote
Humacyte, Inc. (NASDAQ: HUMA) has released its definitive proxy statement for its virtual annual meeting on June 9, 2026. Shareholders will vote on six proposals, including the election of three Class II directors, advisory votes on executive compensation and its frequency, the ratification of PricewaterhouseCoopers LLP as auditor, and a significant increase in authorized common stock from 350,000,000 to 550,000,000 shares. The proxy also details 2025 executive compensation, with CEO Laura E. Niklason receiving over $5.2 million, largely due to stock option awards.
Humacyte regains ex-US rights to Symvess from Fresenius Medical Care
Humacyte has regained the ex-US rights for its investigational bioengineered vessel, Symvess, from Fresenius Medical Care. This move, which was mutually decided, will allow Humacyte to directly pursue the development and potential commercialization of Symvess outside the US. The company plans to seek new partnerships for Symvess and has appointed a VP of market access and global commercial strategy.
Humacyte webcast tackles dialysis access with Phase 3 results due
Humacyte will host a virtual Key Opinion Leader (KOL) event on April 28, 2026, at 8:00 AM ET to discuss the unmet need for hemodialysis patients and provide an overview of its Acellular Tissue Engineered Vessel (ATEV) for arteriovenous access. The event will feature KOLs Prabir Roy-Chaudhury and Mohamad A. Hussain, and interim V012 Phase 3 top-line results are expected this quarter. The ATEV is designed as an alternative to the current standard of care for hemodialysis patients with End-Stage Renal Disease (ESRD) and remains investigational for uses beyond the FDA extremity vascular trauma approval.
Humacyte Expands Commercial and Business Development Opportunities through Realignment of Ex-U.S. Rights to Symvess
Humacyte, Inc. has realigned its ex-U.S. distribution rights for Symvess with Fresenius Medical Care through an amended agreement. This strategic move grants Humacyte exclusive rights to distribute Symvess outside the U.S., allowing the company to fully pursue international commercialization initiatives, including those previously announced in Saudi Arabia and Israel. Fresenius Medical Care will now receive low-single-digit royalties on Humacyte's net sales of Symvess outside the U.S., while the existing U.S. terms remain unchanged.
Humacyte (HUMA) takes ex-U.S. Symvess control as Fresenius retains 8.4% stake
Humacyte, Inc. has amended its distribution agreement with Fresenius Medical Care for Symvess, an acellular tissue engineered vessel. Humacyte now holds exclusive rights for ex-U.S. distribution, with Fresenius receiving low-single-digit royalties, while U.S. distribution terms remain unchanged. Fresenius Medical Care Holdings, Inc. and its parent company retain an 8.4% beneficial ownership stake in Humacyte.
Humacyte regains ex-US rights to Symvess from Fresenius Medical Care
Humacyte has regained ex-US rights to its biotechnology product Symvess from Fresenius Medical Care. This move gives Humacyte full control over the development and commercialization of Symvess outside the United States. Further details about the terms of this agreement were not immediately available.
